Celltex & COVID-19 Clinical Trials
Celltex has three ongoing COVID-19 clinical trials using Celltex’s TRUECELL™ Mesenchymal Stem Cells (MSCs), a Phase III and two Phase II.
Celltex sponsors a COVID-19 Phase III clinical trial with Hospital Juarez, the primary government hospital in Mexico City, to treat severe COVID-19 symptoms. The Company was selected by the Mexican government as the exclusive provider for its MSCs, produced in its Houston, Texas-based lab and this trial has been authorized by COFEPRIS, Mexico’s equivalent to the US FDA.
In the US, Celltex sponsors a COVID-19 Phase II clinical trial that investigates the efficacy of autologous (your own) adipose-tissue (fat) derived MSCs for preventing COVID-19 in high-risk individuals. It also sponsors another COVID-19 Phase II clinical trial that investigates the efficacy of allogeneic (donor) MSCs for treating severe COVID-19 induced symptoms.
These clinical trials are important because it has been shown that severe COVID-19 will cause cytokine release syndrome, or CRS, an acute systemic inflammation resulting in multiple organ failure including heart, liver, kidney, lung and other organs. CRS is a life-threatening complication with a high death rate if the patient is not treated quickly and effectively.
The safety and efficacy of MSCs have been demonstrated in many clinical trials and Celltex MSCs have been used in over 9,000 therapies with no adverse reactions. The immunomodulating and anti-inflammatory properties of MSCs are crucial to strengthening the body’s defense system and combatting COVID-19. In an editorial written by Dr. Ashok K. Shetty, Associate Director at Texas A&M University Institute for Regenerative Medicine, it is shown that intravenous MSC infusions could reduce the overactivation of the immune system and support repair by modulating the lung microenvironment after COVID-19 infection.
Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company founded in 2011 and a pioneer in MSC technology. Celltex is the nation’s leading commercial MSC banking company and focuses on spearheading breakthroughs in regenerative medicine using MSCs. The Company uses its own proprietary technology in its Houston-based, cGMP laboratory to isolate, cryopreserve and grow hundreds of millions of MSCs for therapeutic use.
More Recent News
Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells (MSCs) as a Prophylactic Against COVID-19Read More
Rick Perry Discusses Celltex’s COVID-19 Clinical Trials on Fox News TV
Former U.S. Secretary of Energy and former Governor of Texas, Rick Perry, was on Fox News TV discussing Celltex’s COVID-19 ongoing clinical trials and the ingenuity that will deliver a victory over this virus.Read More